CVC  Takeda Ventures

     Office Locations:

435 Tasso Street, Suite 300
Palo Alto, CA 94301
Phone: 650-328-2900
Fax: 650-328-2922



  • Early
  • Growth
  • Seed



  • Life Sciences & Healthcare



    Takeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a pharmaceutical company and the largest in Japan. TVI assumes the role of Takeda's former venture investment group, Takeda Research Investment, Inc., and remains a wholly owned subsidiary of Takeda America Holdings, Inc.. The new group continues to seek strategic opportunities to complement and extend internal discovery capabilities, but will additionally explore potentially new business avenues for Takeda through external strategic venture activities. Takeda's strategic investment mandate means that while it will consider product, target and technology opportunities at any stage, the firm's focus is on start-up/seed rounds, through mid-stage financings. TVI intends to maintain a diverse investment portfolio, but is presently concentrating on drugs and biotherapeutics to treat cancer, metabolic disorders (obesity, diabetes, and dyslipidemias), cardiovascular disorders, chronic inflammatory disorders (particularly for gastrointestinal and bone and joint diseases) and diseases for the central nervous system (specifically Alzheimers Disease and schizophrenia). Additional areas of strategic importance are regenerative medicines, RNA and DNA modulation, novel vaccines technologies and innovative protein and peptide biotherapeutics. Currently, TVI does not invest in anti-infective diseases, medical devices, or diagnostics platforms.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Graeme Martin Ph.D. President & CEO
    Ilan Zipkin Ph.D. Senior Investment Director
    Yuji Iizawa Senior Investment Director


    Recent Funding Events (trailing 12 months):







      Ribon Therapeutics



      Series B





      Series A





      Series B


    Portfolio companies include:

        web link

      Aquinnah Pharmaceuticals
        web link

      ArmaGen Technologies
        web link

        web link

        web link

      Curidum Medica
        web link

        web link

      Envoy Therapeutics
        web link

      Fate Therapeutics
        web link

      Heptares Therapeutics
        web link

      Juventas Therapeutics
        web link

      Lectus Therapeutics
        web link

        web link

      NGM Biopharmaceuticals
        web link

      Obsidian Therapeutics
        web link

        web link

      Outpost Medicine
        web link

      Palleon Pharmaceuticals
        web link

        web link

      Prosetta Biosciences
        web link

      Redwood Bioscience
        web link

      Ribon Therapeutics
        web link

        web link

        web link

      Xenon Pharmaceuticals
        web link


    Recent News: